Stock comparison
IDEXX Laboratories
PTC Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
PTCT
PTC Therapeutics
Market cap
$5.93B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PTCT | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 50C | IDXX |
| Benjamin Graham | 72B | 12F | IDXX |
| Philip Fisher | 67B | 54C | IDXX |
| Peter Lynch | 63C | 43D | IDXX |
| Joel Greenblatt | 75B | 2F | IDXX |
| Charlie Munger | 79B | 42D | IDXX |
| Terry Smith | 76B | 50C | IDXX |
Side-by-side metrics
| Metric | IDXX | PTCT |
|---|---|---|
| Market cap | $42.11B | $5.93B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | 6.4x |
| ROIC (TTM) | 40.66% | -2.38% |
| Gross margin | 62.05% | 77.84% |
| Net margin | 24.63% | -22.58% |
| Revenue CAGR 5y | 7.56% | 33.89% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs -22.58%+192%
- ROIC (TTM)40.66%vs -2.38%+106%
- Market cap$42.11Bvs $5.93B+86%
PTCT leads on
- P/E (TTM)-vs 39.0x+181%
- Debt / Equity-vs 0.7x+132%
- EV/EBIT6.4xvs 31.6x+80%
- Revenue CAGR 5y33.89%vs 7.56%+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.